Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORIC-944 · 1 trial · 1 indication
RP2D as determined by interval 3+3 dose escalation design
PK of ORIC-944 single agent and in combination with an ARPI
PK of ORIC-944 single agent and in combination with an ARPI
PK of ORIC-944 single agent and in combination with an ARPI
PK of ORIC-944 single agent and in combination with an ARPI
| Arm | Type | Description |
|---|---|---|
| Single Agent Dose Escalation | EXPERIMENTAL | ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles |
| Combination Dose Escalation | EXPERIMENTAL | ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combinations with abiraterone, apalutamide, darolutamide, or enzalutamide |
| Combination Dose Optimization | EXPERIMENTAL | Cohort A and C: ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combination with apalutamide Cohort B and D: ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combination with darolutamide Combinations with abiraterone or enzalutamide may be conducted in the future |
| Name | Type | Description |
|---|---|---|
| ORIC-944 | DRUG | Oral, once daily, continuous |
| Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets | DRUG | Oral, 1000 mg once daily, continuous |
| Apalutamide (Erleada™) 60 mg or 240 mg tablets | DRUG | Oral, 240 mg once daily, continuous |
| Darolutamide (Nubeqa®) 300 mg tablets | DRUG | Oral, 600 mg twice daily, continuous |
| Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets | DRUG | Oral, 160 mg once daily, continuous |
Inclusion Criteria: * Patients with metastatic prostate cancer * Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone * Prior therapies: Part I (single agent ORIC-944 dose escalation): Any number of prior therap...
Top 20 of 54 competitors
ORIC-944 is an investigational small molecule being studied for the treatment of metastatic prostate cancer. It is currently in Phase 1 clinical development, and the ongoing trial is evaluating its safety and efficacy in patients with this condition.
ORIC-944 targets EED, a component of the PRC2 complex. By inhibiting EED, the drug aims to modulate PRC2 activity, which is relevant in cancer biology. This mechanism is being investigated in the context of metastatic prostate cancer.
ORIC-944 is being developed by Oric Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ORIC. The company is conducting clinical trials to evaluate the drug's potential in treating metastatic prostate cancer.
ORIC-944 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients with metastatic prostate cancer to assess the drug's safety and preliminary efficacy.
ORIC-944 is being studied in a Phase 1 clinical trial with the identifier NCT05413421, titled 'Study of ORIC-944 in Patients With Metastatic Prostate Cancer.' This trial is currently recruiting participants and has an estimated enrollment of 275 patients across the United States, Australia, Spain, and the United Kingdom.
ORIC-944 is a distinct investigational compound developed by Oric Pharmaceuticals. No alternative names for this drug have been disclosed in the available information. It is being studied specifically for its potential role in treating metastatic prostate cancer.